{"product_id":"drugdrug-interactions-for-therapeutic-biologics-9781118032169","title":"DrugDrug Interactions for Therapeutic Biologics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eStrategize, plan, and execute comprehensive drug-drug interaction assessments for therapeutic biologics\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOffering both theory and practical guidance, this book fully explores drug-drug interaction assessments for therapeutic biologics during the drug development process. It draws together and analyzes all the latest findings and practices in order to present our current understanding of the topic and point the way to new research. Case studies and examples, coupled with expert advice, enable readers to better understand the complex mechanisms of biologic drug-drug interactions.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDrug-Drug Interactions for Therapeutic Biologics\u003c\/i\u003e features contributions from leading international experts in all areas of therapeutic biologics drug development and drug-drug interactions. The authors'' contributions reflect a thorough review and analysis of the literature as well as their own firsthand laboratory experience. Coverage includes such essential topics as:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e\n\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePREFACE ix\u003c\/p\u003e \u003cp\u003eABOUT THE EDITORS xi\u003c\/p\u003e \u003cp\u003eCONTRIBUTORS xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS: A JOURNEY JUST BEGINNING 1\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHonghui Zhou and Bernd Meibohm\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. PHARMACOKINETIC AND PHARMACODYNAMIC-BASED DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 5\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDan Lu, Sandhya Girish, Frank-Peter Theil, and Amita Joshi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. DRUG INTERACTION ASSESSMENT STRATEGIES: SMALL MOLECULES VERSUS THERAPEUTIC PROTEINS 39\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eShannon Dallas, Carlo Sensenhauser, Souvik Chattopadhyay, and Jose Silva\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. MODEL-INDEPENDENT AND MODEL-BASED METHODS TO ASSESS DRUG–DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 63\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDi Wu and Jeffrey S. Barrett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. UTILITY OF IN VITRO METHODS IN DRUG–DRUG INTERACTION ASSESSMENT AND PREDICTION FOR THERAPEUTIC BIOLOGICS 73\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eTheresa Nguyen, Narendra Kishnani, and Raymond Evers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. USE OF ANIMAL MODELS FOR PROJECTION OF CLINICAL DRUG–DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 103\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEugenia Kraynov and Martin E. Dowty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. THE COCKTAIL APPROACH AND ITS UTILITY IN DRUG–DRUG INTERACTION ASSESSMENTS FOR THERAPEUTIC PROTEINS 111\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAlexander Jetter and Uwe Fuhr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. LOGISTIC CONSIDERATIONS IN STUDY DESIGN FOR BIOLOGIC DRUG–DRUG\u003c\/b\u003e \u003cb\u003eINTERACTION ASSESSMENTS 119\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMin Zhu and Yu-Nien (Tom) Sun\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. STATISTICAL CONSIDERATIONS IN ASSESSING DRUG–DRUG INTERACTIONS FOR THERAPEUTIC BIOLOGICS 139\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eChuanpu Hu and Honghui Zhou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10. SCIENTIFIC PERSPECTIVES ON THERAPEUTIC PROTEIN DRUG–DRUG INTERACTION ASSESSMENTS 155\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHong Zhao, Lei Zhang, Kellie Reynolds, and Shiew-Mei Huang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11. DISEASE–DRUG–DRUG INTERACTION ASSESSMENTS FOR TOCILIZUMAB—A MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR TO TREAT PATIENTS WITH RHEUMATOID ARTHRITIS 191\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eXiaoping Zhang and Barbara J. Brennan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12. DRUG–DRUG INTERACTIONS FOR ETANERCEPT—A FUSION PROTEIN 207\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJoan Korth-Bradley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13. DRUG INTERACTIONS OF CYTOKINES AND ANTICYTOKINE THERAPEUTIC PROTEINS 215\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJ. Greg Slatter, Larry C. Wienkers, and Leslie J. Dickmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14. DRUG INTERACTIONS FOR GROWTH FACTORS AND HORMONES 239\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eYow-Ming C. Wang and Tarundeep Kakkar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15. DRUG–DRUG INTERACTIONS FOR NUCLEIC ACID-BASED DERIVATIVES 257\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJian Wang and Hong Zhao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAPPENDIX: MONOGRAPHS FOR DRUG-DRUG\u003c\/b\u003e \u003cb\u003eINTERACTIONS OF THERAPEUTICS BIOLOGICS 275\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJocelyn Leu, Simone Kasek, Christine Li, Wararat Limothai, Dora Babu Madhura, Chetan Rathi, Sumit Rawal, Josiah Ryman, Margaret Thomson, Ashit Trivedi, Honghui Zhou, and Bernd Meibohm\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eINDEX 351\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49406823530839,"sku":"9781118032169","price":999.99,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/drugdrug-interactions-for-therapeutic-biologics-9781118032169","provider":"Book Curl","version":"1.0","type":"link"}